髓源性抑制细胞通过抑制炎症反应减轻小鼠肾脏缺血再灌注损伤

doi:10.3877/cma.j.issn.1674-3903.2023.01.006

中华移植杂志(电子版) ›› 2023, Vol. 17 ›› Issue (01) : 42 -46. doi: 10.3877/cma.j.issn.1674-3903.2023.01.006

论著

髓源性抑制细胞通过抑制炎症反应减轻小鼠肾脏缺血再灌注损伤

张星哲¹, 郑秉暄¹, 邓格¹, 豆猛¹, 石玉婷¹, 卫田¹, 郭映聪¹, 韩锋², 赵艳龙³, 丁晨光¹, 田普训¹^,^†(

)

^1. 710061　西安交通大学第一附属医院肾脏病医院肾移植科　西安交通大学器官移植研究所
^2. 710068　西安，陕西省人民医院烧伤整形医学美容外科
^3. 710003　西安，陕西省中医医院肾病医院血液透析室

收稿日期:2023-01-16 出版日期:2023-02-25
通信作者: 田普训
基金资助:
国家自然科学基金(81870514，82100798); 陕西省重大基础研究项目(2017ZDJC-09)

Myeloid-derived suppressor cells alleviate renal ischemia-reperfusion injury in mice by inhibiting inflammatory response

Xingzhe Zhang¹, Bingxuan Zheng¹, Ge Deng¹, Meng Dou¹, Yuting Shi¹, Tian Wei¹, Yingcong Guo¹, Feng Han², Yanlong Zhao³, Chenguang Ding¹, Puxun Tian¹^,^†()

^1. Department of Kidney Transplantation, Division of Kidney Diseases, First Affiliated Hospital, Xi′an Jiaotong University School of Medicine, Institute of Organ Transplantation, Xi′an Jiaotong University, Xi′an 710061, China
^2. Department of Burn and Plastic Surgery, Shaanxi Provincial People′s Hospital, Xi′an 710068, China
^3. Department of Hemodialysis, Hospital of Nephropathy, Shaanxi Provincial Hospital of Chinese Medicine, Xi′an 710003, China

Received:2023-01-16 Published:2023-02-25
Corresponding author: Puxun Tian

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

张星哲, 郑秉暄, 邓格, 豆猛, 石玉婷, 卫田, 郭映聪, 韩锋, 赵艳龙, 丁晨光, 田普训. 髓源性抑制细胞通过抑制炎症反应减轻小鼠肾脏缺血再灌注损伤[J/OL]. 中华移植杂志(电子版), 2023, 17(01): 42-46.

Xingzhe Zhang, Bingxuan Zheng, Ge Deng, Meng Dou, Yuting Shi, Tian Wei, Yingcong Guo, Feng Han, Yanlong Zhao, Chenguang Ding, Puxun Tian. Myeloid-derived suppressor cells alleviate renal ischemia-reperfusion injury in mice by inhibiting inflammatory response[J/OL]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 42-46.

目的

探讨髓源性抑制细胞(MDSC)对小鼠肾脏缺血再灌注损伤(IRI)的作用及其可能机制。

方法

15只雄性C57BL/6小鼠分为假手术组、IRI组、IRI＋MDSC组，每组5只。所有小鼠采取背部双侧切口，切除左肾。假手术组小鼠暴露右肾50 min后缝合，IRI组夹闭右侧肾蒂50 min后开放灌注，IRI＋MDSC组于开放灌注1 h内经尾静脉输注使用C57BL/6小鼠骨髓细胞诱导的MDSC。恢复灌注后24h，留取小鼠血液及肾脏和脾脏组织标本，观察肾组织病理变化，检测血尿素氮和肌酐水平。ELISA检测血清中细胞因子TNF-α、IFN-γ、IL-6和IL-10水平。流式细胞术检测脾脏中T细胞活化。符合正态分布的计量数据以均数±标准差(±s)表示，采用单因素方差分析比较。

结果

与IRI组相比，IRI＋MDSC组小鼠肾功能明显改善，血尿素氮和血清肌酐水平均低于IRI组([(29.6±3.1)和(34.1±1.4)mmol/L，(105±13)和(176±20)μmol/L，P均<0.05]。IRI＋MDSC组肾小管上皮细胞坏死程度、范围及炎性细胞浸润程度较IRI组减轻，Paller评分优于IRI组[(55.0±3.0)和(40.6±6.7)分，P<0.05)]。IRI＋MDSC组血清中促炎性细胞因子水平均低于IRI组(P均<0.05)，TNF-α分别为(452±55)和(605±73)pg/mL，IFN-γ分别为(405±101)和(576±76)pg/mL，IL-6分别为(459±37)和(863±20)pg/mL；而具有抗炎作用的细胞因子IL-10水平则高于IRI组，分别为(1519±244)和(926±66)pg/mL。同时，IRI＋MDSC组小鼠脾脏中活化的CD4^＋T细胞和CD8^＋T细胞水平均低于IRI组，分别为(15.6±1.3)%和(20.2±1.4)%、(31.8±1.8)%和(40.4±2.0)%，差异均有统计学意义(P均<0.05)。

结论

体外诱导MDSC可通过抑制IRI后机体的炎症反应，减轻肾损伤。

关键词: 髓源性抑制细胞, 缺血再灌注损伤, 肾脏, 炎症反应, 小鼠

Objective

To investigate the effect and mechanism of myeloid-derived suppressor cells (MDSCs) on renal ischemia-reperfusion injury (IRI) in mice.

Methods

A total of 15 male C57BL/6 mice were randomly divided into Sham group (n=5), IRI group (n=5), IRI combined with MDSCs transfusion group (IRI+ MDSC group, n=5). Twenty-four hours after perfusion, blood and kidney tissue samples of mice were collected, and the pathological changes of kidney tissue were observed by hematoxylin-eosin (HE) staining, and the contents of blood urea nitrogen (BUN) and serum creatinine (Cr) were detected. Serum levels of cytokines TNF-α, IFN-γ, IL-6 and IL-10 were detected by ELISA. T-cell activation in spleen was detected by flow cytometry. One-way ANOVA was used to compare the differences between multiple groups.

Results

Compared with the IRI group, the IRI+ MDSC group showed significantly improved renal function [Cr: (105±13) and (176±20) μmol/L, BUN: (34.1±1.4) and (29.6±3.1) mmol/L, P<0.05]. The necrosis degree and range of renal tubular epithelial cells and inflammatory cell infiltration degree were reduced in the IRI+ MDSC group. Paller scores were better in the IRI+ MDSC group than those in the IRI group [(55.0±3.0) vs. (40.6±6.7), P<0.05]. Serum levels of pro-inflammatory cytokines [TNF-α: (452±55) vs. (605±73) pg/mL, IFN-γ: (405±101) vs. (576±76) pg/mL, and IL-6: (459±37) vs. (863±20) pg/mL] in the IRI+ MDSC group were lower than those in IRI group (all P<0.05), respectively. However, the level of anti-inflammatory cytokine IL-10 was higher in the IRI+ MDSC group [(1519±244) pg/mL]. At the same time, the levels of activated CD4⁺ T cells and CD8⁺ T cells in spleen of the IRI+ MDSC group were lower than those of the IRI group, which were (15.6±1.3)% and (20.2±1.4)%, (31.8±1.8)% and (40.4±2.0)%, respectively, and the differences were statistically significant (all P<0.05).

Conclusion

MDSCs induced in vitro can alleviate renal injury by inhibiting the inflammatory response after IRI.

Key words: Myeloid-derived suppressor cell, Ischemia-reperfusion injury, Renal, Inflammatory response, Mice

图1 GM-CSF联合PGE2体外诱导的MDSC表面标志物及其抑制功能实验注：GM-CSF.粒细胞-巨噬细胞集落刺激因子；PGE2.前列腺素E2; MDSC.髓源性抑制细胞；a和b.流式细胞术检测MDSC表面标志物及比例；c．流式细胞术检测MDSC对CD8^＋ T细胞增殖的抑制功能；^*.P<0.05

表1 三组小鼠肾功能、细胞因子和T细胞活化水平比较(±s)

组别	只数	肾功能		细胞因子(pg/mL)				T细胞活化(%)
组别	只数	BUN(mmol/L)	Cr(μmol/L)	TNF-α	IFN-γ	IL-6	IL-10	CD4^＋CD44^＋CD62L^－	CD8^＋CD44^＋CD62L^－
假手术组	5	15.8±1.8	27±6	86±23	104±18	96±29	114±8	13.0±2.2	21.6±2.2
IRI组	5	34.1±1.4^a	176±20^a	605±73^a	576±76^a	863±20^a	926±66^a	20.2±1.4^a	40.4±2.0^a
IRI＋MDSC组	5	29.6±3.1^a，b	105±13^a，b	452±55^a，b	405±101^a，b	459±37^a，b	1 519±244^a，b	15.6±1.3^a，b	31.8±1.8^a，b

表1 三组小鼠肾功能、细胞因子和T细胞活化水平比较(±s)

组别	只数	肾功能		细胞因子(pg/mL)				T细胞活化(%)
组别	只数	BUN(mmol/L)	Cr(μmol/L)	TNF-α	IFN-γ	IL-6	IL-10	CD4^＋CD44^＋CD62L^－	CD8^＋CD44^＋CD62L^－
假手术组	5	15.8±1.8	27±6	86±23	104±18	96±29	114±8	13.0±2.2	21.6±2.2
IRI组	5	34.1±1.4^a	176±20^a	605±73^a	576±76^a	863±20^a	926±66^a	20.2±1.4^a	40.4±2.0^a
IRI＋MDSC组	5	29.6±3.1^a，b	105±13^a，b	452±55^a，b	405±101^a，b	459±37^a，b	1 519±244^a，b	15.6±1.3^a，b	31.8±1.8^a，b

图2 三组小鼠恢复灌注后24 h肾组织病理检查结果(HE ×400)注：IRI.缺血再灌注损伤；MDSC.髓源性抑制细胞；a.假手术组；b. IRI组；c. IRI＋MDSC组

1	Nieuwenhuijs-Moeke GJ, Pischke SE, Berger SP, et al. Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair[J]. J Clin Med, 2020，9(1)：253.
2	Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018，19(2)：108-119.
3	Dugast AS, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion[J]. J Immunol, 2008，180(12)：7898-7906.
4	Ji J, Zhuang Y, Lin Z, et al. Interferon-γ-induced myeloid-derived suppressor cells aggravate kidney ischemia-reperfusion injury by regulating innate immune cells[J]. Nephron, 2022，146(1)：99-109.
5	Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat[J]. J Clin Invest, 1984，74(4)：1156-1164.
6	Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018，19(2)：108-119.
7	Dugast AS, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion[J]. J Immunol, 2008，180(12)：7898-7906.
8	Tomić S, Joksimović B, Bekić M, et al. Prostaglanin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets[J]. Front Immunol, 2019，10：475.
9	Koehn BH, Apostolova P, Haverkamp JM, et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells[J]. Blood, 2015, 126(13)：1621-1628.
10	Medzhitov R. Inflammation 2010: new adventures of an old flame[J]. Cell, 2010, 140(6)：771-776.
11	Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage[J]. Nat Rev Immunol, 2010，10(12)：826-837.
12	Kurts C, Panzer U, Anders HJ, et al. The immune system and kidney disease: basic concepts and clinical implications[J]. Nat Rev Immunol, 2013，13(10)：738-753.
13	Gu J, Sun P, Zhao H, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice[J]. Crit Care, 2011，15(3)：R153.
14	Rao J, Lu L, Zhai Y. T cells in organ ischemia reperfusion injury[J]. Curr Opin Organ Transplant, 2014，19(2)：115-120.
15	Pegues MA, McWilliams IL, Szalai AJ. C-reactive protein exacerbates renal ischemia-reperfusion injury: are myeloid-derived suppressor cells to blame？[J]. Am J Physiol Renal Physiol, 2016，311(1)：F176-F181.
16	Ren JP, Wang L, Zhao J, et al. Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection[J]. Immunology, 2017，150(2)：213-220.
17	Messmann JJ, Reisser T, Leithäuser F, et al. In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity[J]. Blood, 2015，126(9)：1138-1148.
18	Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells[J]. Cancer Res, 2007，67(9)：4507-4513.
19	Sinha P, Parker KH, Horn L, et al. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα[J]. Eur J Immunol, 2012，42(8)：2052-2059.
20	黎贵芸，冯强，胡雄，等. COX-2/PGE2在肿瘤发生发展和重塑肿瘤微环境中的研究进展[J]. 中国肿瘤临床，2020，47(16)：840-846.

[1]	唐亦骁, 陈峻, 连正星, 胡海涛, 鲁迪, 徐骁, 卫强. 白果内酯对小鼠肝缺血再灌注损伤保护作用研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 278-282.
[2]	杨柳, 陈佳, 孙雅娟, 陈娇, 谭明超, 龚明福. 抗中性粒细胞胞浆抗体相关性血管炎的胸部CT 及临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 744-749.
[3]	李智, 冯芸. NF-κB 与MAPK 信号通路及其潜在治疗靶点在急性呼吸窘迫综合征中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 840-843.
[4]	孙璐, 蒋亚玲, 陈凌君. 布托啡诺对脑缺血再灌注损伤大鼠神经炎症和JAK2/STAT3信号通路的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 344-350.
[5]	周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[6]	程柏凯, 杨光. 高胰岛素-正葡萄糖钳夹技术评估慢性肾脏病患者胰岛素抵抗的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 334-339.
[7]	崔文鹏. 腹膜透析在老年终末期肾脏疾病患者中的应用[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 300-300.
[8]	王小龙, 吴杰, 冯哲, 文浩, 段姝伟, 梁爽, 蔡广研. 心内科病房急性肾损伤且行肾脏替代治疗患者短期预后不良的危险因素分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 241-248.
[9]	冯熔熔, 苏晓乐, 王利华. 慢性肾脏病患者并发心血管疾病相关生物标志物研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 273-278.
[10]	郭俊楠, 林惠, 任艺林, 乔晞. 氨基酸代谢异常在急性肾损伤向慢性肾脏病转变中的作用研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 283-287.
[11]	李京, 牛博, 刘晓蓓, 魏新雪, 黄荣. circ-SESN2 沉默靶向调控miRNA-23a-5p/ULK1 在神经细胞氧化应激损伤中的作用机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 263-272.
[12]	邱英鹏, 李欣雨, 邱海波, 刘松桥, 张凌, 于湘友, 秦秉玉, 蒲莹莹, 赵佳钰, 刘永军, 肖月, 杨毅. 连续性肾脏替代治疗质量控制指标体系的建立及验证[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 351-357.
[13]	向阳, 史黎炜, 肖月, 邱海波, 杨毅, 刘松桥, 邱英鹏, 张莹. 连续性肾脏替代治疗在我国五地区重症医学科的效率分析[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 358-363.
[14]	奚培培, 周加军. 慢性肾脏病患者肌少症机制和诊治的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 491-495.
[15]	孙双权, 孙玮玮, 王勇, 方道成, 温晖. 肾脏混合性上皮和间质肿瘤一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 512-515.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Myeloid-derived suppressor cells alleviate renal ischemia-reperfusion injury in mice by inhibiting inflammatory response

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Myeloid-derived suppressor cells alleviate renal ischemia-reperfusion injury in mice by inhibiting inflammatory response